Using network pharmacology analysis and molecular docking of quercetin compound for treatment of Alzheimer

Alzheimer's disease is currently increasing in risk with age. This study investigates the inhibitory activity of Quercetin (QC) compounds in slowing the progression of Alzheimer's disease (AD). The research employs network pharmacology and molecular docking methods. Furthermore, it conducts screening of important herbal medicines from traditional Chinese medicine and integrates them with the GeneCards database and AD-related targets. Overlapping herbal medicines and targets have been identified as significant candidates. A total of 10 target genes have been selected for QC in AD treatment. The JUN gene shows the highest binding affinity. Gene Ontology (GO) analysis was performed to identify AD-related biological processes and neural cell components. Additionally, 10 candidate targets with homologous genes participating in signaling pathways have been identified. QC binding molecules exhibit high binding affinity for 10 target proteins, elucidating candidate targets for QC in alleviating AD. The study explores protein-protein interactions and associated signaling pathways, confirming QC's inhibition of AD. This provides a basis for AD therapy monitoring.